Literature DB >> 22963925

NEDD9 rs760678 polymorphism and the risk of Alzheimer's disease: a meta-analysis.

Yucheng Wang1, Liqing Bi, Hui Wang, Yanyan Li, Qun Di, Wei Xu, Yun Qian.   

Abstract

The NEDD9 rs760678 polymorphism has been extensively investigated for association to Alzheimer's disease (AD), however, results of different studies have been inconsistent. The objective of this study is to assess the relationship of NEDD9 rs760678 polymorphism and AD risk by using meta-analysis. Systematic searches of electronic databases Pubmed and Embase, as well as hand searching of the references of identified articles were performed. Statistical analyses were performed using software Revman 4.2 and STATA 11.0. A total of 4436 cases and 4420 controls in 11 case-control studies were included. The results indicated that the homozygote GG had a 13% decreased risk of AD, when compared with the C allele carriers (CC+CG) (OR=0.87, 95%CI=0.77-0.99, P=0.04 for GG vs. CG+CC). In the subgroup analysis by ethnicity, significant decreased risk was associated with homozygote GG or G allele carriers in Caucasians (OR=0.84, 95%CI=0.74-0.96, P=0.008 for GG vs. CG+CC; OR=0.79, 95%CI=0.69-0.91, P=0.001 for GG vs. CC; OR=0.90, 95%CI=0.84-0.96, P=0.002 for G vs. C), but not in Asians. This meta-analysis suggests that the GG genotype of NEDD9 rs760678 polymorphism would be a protective factor for AD in Caucasians but not in Asians. To further evaluate the effect of gene-gene and gene-environmental interactions between NEDD9 rs760678 polymorphism and the risk of AD, more studies with larger number of subjects are required. Crown
Copyright © 2012. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22963925     DOI: 10.1016/j.neulet.2012.08.044

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Semiparametric Bayes conditional graphical models for imaging genetics applications.

Authors:  Suprateek Kundu; Jian Kang
Journal:  Stat (Int Stat Inst)       Date:  2016-11-27

2.  Overexpression of Nedd9 is a prognostic marker of human gastric cancer.

Authors:  Qi Zhang; Huiju Wang; Yingyu Ma; Jun Zhang; Xujun He; Jie Ma; Zhong-Sheng Zhao
Journal:  Med Oncol       Date:  2014-06-07       Impact factor: 3.064

Review 3.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Authors:  Elena Shagisultanova; Anna V Gaponova; Rashid Gabbasov; Emmanuelle Nicolas; Erica A Golemis
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

4.  Nedd9 restrains renal cystogenesis in Pkd1-/- mice.

Authors:  Anna S Nikonova; Olga V Plotnikova; Victoria Serzhanova; Andrey Efimov; Igor Bogush; Kathy Q Cai; Harvey H Hensley; Brian L Egleston; Andres Klein-Szanto; Tamina Seeger-Nukpezah; Erica A Golemis
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-19       Impact factor: 11.205

5.  The Contribution Plot: Decomposition and Graphical Display of the RV Coefficient, with Application to Genetic and Brain Imaging Biomarkers of Alzheimer's Disease.

Authors:  JinCheol Choi; Donghuan Lu; Mirza Faisal Beg; Jinko Graham; Brad McNeney
Journal:  Hum Hered       Date:  2019-08-20       Impact factor: 0.444

6.  Elevated expression of NEDD9 is associated with metastatic activity in gastric cancer.

Authors:  Si-Sen Zhang; Li-Hua Wu; Qing Liu; Kui-Sheng Chen; Xie-Fu Zhang
Journal:  Onco Targets Ther       Date:  2015-03-10       Impact factor: 4.147

7.  Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.

Authors:  Tim N Beck; Emmanuelle Nicolas; Meghan C Kopp; Erica A Golemis
Journal:  Oncoscience       Date:  2014-07-23

8.  The Prognostic Role of NEDD9 and P38 Protein Expression Levels in Urinary Bladder Transitional Cell Carcinoma.

Authors:  Ola A Harb; Rasha Haggag; Maged M Ali; Shereen El Shorbagy; Abeer M Abdelbary; Lobna A Abdelaziz; Reham A Salim; Khaled M Abdel Wahab
Journal:  J Oncol       Date:  2017-01-17       Impact factor: 4.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.